SG11202000724XA - Methods and compositions for the treatment of cancer - Google Patents

Methods and compositions for the treatment of cancer

Info

Publication number
SG11202000724XA
SG11202000724XA SG11202000724XA SG11202000724XA SG11202000724XA SG 11202000724X A SG11202000724X A SG 11202000724XA SG 11202000724X A SG11202000724X A SG 11202000724XA SG 11202000724X A SG11202000724X A SG 11202000724XA SG 11202000724X A SG11202000724X A SG 11202000724XA
Authority
SG
Singapore
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Application number
SG11202000724XA
Inventor
Yosef Refaeli
Brian C Turner
Gregory Alan Bird
Original Assignee
Taiga Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiga Biotechnologies Inc filed Critical Taiga Biotechnologies Inc
Publication of SG11202000724XA publication Critical patent/SG11202000724XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
SG11202000724XA 2017-08-03 2018-08-01 Methods and compositions for the treatment of cancer SG11202000724XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762540901P 2017-08-03 2017-08-03
PCT/US2018/044740 WO2019028098A1 (en) 2017-08-03 2018-08-01 Methods and compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
SG11202000724XA true SG11202000724XA (en) 2020-02-27

Family

ID=65234162

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000724XA SG11202000724XA (en) 2017-08-03 2018-08-01 Methods and compositions for the treatment of cancer

Country Status (10)

Country Link
US (1) US20200155600A1 (en)
EP (1) EP3661953A4 (en)
JP (1) JP2020529847A (en)
KR (1) KR20200036874A (en)
CN (1) CN111094328A (en)
AU (1) AU2018308982A1 (en)
CA (1) CA3071448A1 (en)
IL (1) IL272147A (en)
SG (1) SG11202000724XA (en)
WO (1) WO2019028098A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022527117A (en) * 2019-04-08 2022-05-30 タイガ バイオテクノロジーズ，インク． Compositions and Methods for Cryopreservation of Immune Cells
AU2020274117A1 (en) * 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358739B1 (en) * 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
AU2002228722B2 (en) * 2000-11-01 2007-01-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Expression vectors able to elicit improved immune response and methods of using same
EP1572933A4 (en) * 2002-02-13 2007-09-05 Univ Duke Modulation of immune response by non-peptide binding stress response polypeptides
AU2004316996A1 (en) * 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
KR101441843B1 (en) * 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 Conditionally immortalized long-term stem cells and methods of making and using such cells
CA2735522C (en) * 2008-08-28 2017-04-18 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
AU2013292330B2 (en) * 2012-07-20 2018-07-12 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9365825B2 (en) * 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
EP2986311B1 (en) * 2013-04-18 2018-11-07 TILT Biotherapeutics Oy Enhanced adoptive cell therapy
CA3035209A1 (en) * 2017-08-03 2019-02-07 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US10149898B2 (en) * 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Also Published As

Publication number Publication date
EP3661953A4 (en) 2021-04-14
AU2018308982A1 (en) 2020-02-13
EP3661953A1 (en) 2020-06-10
US20200155600A1 (en) 2020-05-21
CN111094328A (en) 2020-05-01
CA3071448A1 (en) 2019-02-07
KR20200036874A (en) 2020-04-07
JP2020529847A (en) 2020-10-15
WO2019028098A1 (en) 2019-02-07
IL272147A (en) 2020-03-31

Similar Documents

Publication Publication Date Title
IL268406A (en) Compositions and methods for the treatment of hemoglobinopathies
IL258955A (en) Compositions and methods for treatment of cancer
IL267247B (en) Compositions and methods for treating cancer
IL269150A (en) Compositions and methods for treating cancer
IL266053A (en) Compositions and methods for treating ezh2-mediated cancer
IL276808A (en) Compositions and methods for cancer treatment
IL268814A (en) Compositions and methods for treatment of cancer
HK1247630A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
ZA201900960B (en) Methods and compositions for the treatment of cancer
IL269157A (en) Compositions and methods for treating cancer
EP3353204A4 (en) Methods and compositions for treatment of cancer
IL263793A (en) Compounds and compositions for the treatment of cancer
IL266486A (en) Pharmaceutical compositions and methods for the treatment of cancer
IL280587B (en) Flurocytidine derivatives and its composition for the treatment of cancer
EP3328372A4 (en) Compositions and methods of treating cancer
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
EP3185910A4 (en) Methods and compositions for the treatment of cancer
HK1255695A1 (en) Composition and methods for the treatment of blepharoptosis
EP3688023A4 (en) Methods and compositions for cancer treatment
IL255169A0 (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer
IL272147A (en) Methods and compositions for the treatment of cancer
IL272782A (en) Compositions and methods for treating cancer
EP3681498A4 (en) Methods and compositions for the treatment of cancer
EP3515431A4 (en) Compositions and methods for treatment of cancer
IL280262A (en) Compositions and methods for the treatment of cancer